According to published studies¹, individuals with a high genetic risk (top 20% of the Polygenic Risk Score – PRS) are 91% more likely to develop coronary artery disease compared to those with low PRS (bottom 20%). However, even individuals at high genetic risk can reduce their risk of coronary artery disease by up to 50% through healthy lifestyle choices such as quitting smoking, engaging in physical activity, maintaining a healthy weight, and following a tailored diet.
The test combines 31 genetic variants with GENOSOPHY®’s award-winning algorithm, ensuring high reliability in assessing genetic risk.
This test estimates the relative risk of coronary artery disease in the general population (excluding familial genetic risk). It is recommended for:
Individuals with intermediate risk for cardiovascular disease, where PRS assessment may significantly improve clinical decision-making accuracy.
Younger individuals who wish to assess their long-term risk for cardiovascular conditions.
Diagnosis: More accurate identification of individuals with increased genetic risk for coronary artery disease who may require closer monitoring.
Prognosis: Reliable prediction of the risk of cardiac events, contributing to personalized preventive strategies.
Management: Design of personalized preventive interventions in diet and lifestyle based on genetic risk.
Genetic Risk Assessment for Dyslipidemias
According to published studies¹², individuals with a high genetic score have up to a 45% higher risk of lipid disorders. Specifically, the relative risk increases are:
Total Cholesterol (TC): 13% higher
LDL Cholesterol: 18% higher
Triglycerides (TAG): 39% higher
TAG:HDL Ratio: 45% higher
Even for individuals at high genetic risk, personalized nutrition can reduce the risk of dyslipidemia and improve their lipid profile.
The GENOSOPHY genetic test assesses the risk of lipid disorders using 2 Polygenic Risk Scores (PRS) and analyzes 14 genetic variants through its award-winning algorithm.
The test estimates the relative risk for lipid disorders in the general population and is recommended for:
Younger individuals who wish to evaluate their risk of elevated LDL cholesterol and triglycerides or low HDL cholesterol levels.
Individuals interested in adjusting their diet and lifestyle based on their genetic profile to reduce the risk of dyslipidemia.
Diagnosis: Identification of individuals with increased genetic risk for dyslipidemia.
Prognosis: Reliable risk prediction of elevated lipid levels, supporting personalized preventive strategies.
Management:
Personalized nutritional and lifestyle interventions to regulate blood lipid levels.
Selection of preventive strategies, especially for those with high genetic risk, following international clinical guidelines.
According to published studies (Table 1), individuals carrying pathogenic variants are up to 7.5 times more likely to develop thrombosis. In carriers of multiple variants, the risk is even higher.
GENOSOPHY’s genetic test assesses thrombosis risk by analyzing 11 variants with its award-winning algorithm, enabling personalized interventions to lower the risk or improve disease management.
This test estimates the relative risk of thrombosis in the general population and is recommended for:
Individuals with a family history of thromboembolic events
Women with a history of recurrent pregnancy loss
Individuals looking to tailor their lifestyle and treatment approach based on their genetic profile
Diagnosis:
Identification of individuals with increased genetic risk for thrombosis, allowing timely intervention and personalized medical monitoring
Prognosis:
Reliable risk prediction for venous and arterial thrombosis, supporting personalized preventive strategies
Management:
Design of personalized preventive strategies including tailored diet, anticoagulant use, and individualized monitoring
Selection of prevention strategies based on international clinical guidelines, especially for high-risk individuals
| Gene | Polymorphism | Effect | Association | References |
|---|---|---|---|---|
| MTHFR | C677T | Increased risk of thrombosis and pregnancy loss | Thrombosis, Pregnancy Loss | PMID: 29212064, 9669991 |
| MTHFR | A1298C | Increased risk of thrombosis and pregnancy loss | Thrombosis, Pregnancy Loss | PMID: 29212064, 9669991 |
| Factor II | G20210A | 7.5x higher risk of thrombosis during pregnancy | Thrombosis, Pregnancy Loss | PMID: 10666427 |
| Factor V | Leiden G1691A | 3x risk (heterozygous), 18x (homozygous) | Thrombosis, Pregnancy Loss | PMID: 14996674 |
| Factor XIII | V34L | Protective effect against thrombosis | Thrombosis, Pregnancy Loss | PMID: 16740590, 16938111 |
| PAI-1 | 4G/4G | Increased plasminogen levels, increased risk | Thrombosis, Pregnancy Loss | PMID: 11091191, 25250948 |
| FGB | -455G>A | Elevated fibrinogen levels | Stroke, Heart Attack, Pregnancy Loss | PMID: 3626001, 23926530 |
| ApoE | E4 | Associated with venous thrombosis in women | Thrombosis, Pregnancy Loss | PMID: 22006422, 24221911 |
| ACE | DEL/DEL | Increased risk of thrombosis and pregnancy loss | Thrombosis, Pregnancy Loss | PMID: 12864773, 11085286 |
| GPIa | C807T | Increased platelet aggregation | Thrombosis, Stroke, Heart Attack | PMID: 16214444, 11703818 |
| GPIIIa | PIA2 | Increased platelet aggregation, reduced response to antithrombotics | Thrombosis, Heart Attack | PMID: 8598867, 11723016 |
Collection of a saliva sample
Analysis of 56 genetic variants and calculation of relative risks using GENOSOPHY®’s award-winning algorithm
Delivery of results in 5–6 weeks
Based on genetic test results and each individual’s genetic profile, GENOSOPHY® offers additional services to maximize the effectiveness of preventive interventions:
Genetic counseling
Personalized diet plans based on genetic profile
Nutritional consulting
Khera et al., N Engl J Med 2016;375:2349-2358 / DOI: 10.1056/NEJMoa160508
Wuni et al., Br J Nutr 2024;132(5):575-589 / DOI: 10.1017/S0007114524001594
Park et al., Nutrients 2020;12(12):3840 / DOI: 10.3390/nu12123840
